Trial recruitment is speedier in France
This article was originally published in Scrip
Leem, the French pharmaceutical industry association, has revealed three trends in the recruitment of patients for clinical trials in the country: more, faster and better. Its fourth biennial survey of international Phase II and III trials carried out at least partially in France in 2006 and 2007 shows that the country has become more attractive for trial sponsors, but also that it is struggling to keep up with its European neighbours.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.